Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes

Therapeutic Targets in African-American Youth With Type 2 Diabetes

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02960659

Enrollment

Registered

2016-11-10

Start date

2017-05-09

Completion date

2022-05-20

Last updated

2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Diabetes, Metformin, Glucose

Brief summary

Background: The pill metformin treats diabetes. But it does not work for all youth, especially African-Americans. The injectable Liraglutide treats type 2 diabetes in adults. Researchers want to understand how these drugs work and if they decrease excess sugar made by the liver in youth with type 2 diabetes. Objective: To test if using liraglutide and metformin are better than just metformin for decreasing excess sugar produced by the liver in African-American youth with type 2 diabetes. Eligibility: African-Americans ages 12-25 with type 2 diabetes Design: Visit 1: Participants will be screened with medical history, physical exam, and blood and urine tests. Participants will stop taking diabetes medicines for 1 week. They will learn how to check blood sugars at home twice a day. Visit 2: Overnight at the clinic. Participants will have: Vital signs taken. Pregnancy test. A thin plastic tube (IV catheter) be inserted in each forearm by needle. Blood drawn several times after drinking a sweet drink. X-ray of total body fat. Urine and stool collected. Breath tests while wearing a clear hood for up to 45 minutes. For several hours, participants can have only water. At 4 a.m. they will get sugar and fat with nonradioactive isotopes in one IV. Blood will be collected. Every 30 minutes from 9 a.m. to 2 p.m., they will drink small amounts of a shake and have blood drawn. Participants will be randomly assigned to take either both study drugs daily or just metformin daily. Visits 3-4: Participants will bring their blood sugar records and have blood tests. Visit 5, after 3 months: Repeat of visit 2....

Detailed description

Type 2 Diabetes in youth is an emerging public health concern that disproportionately affects minority children. Among minority youth, African-Americans have the highest complication rates, yet the reasons underlying this health disparity are not fully understood. Furthermore, current treatment options are limited, and African-American youth have high treatment failure rates. Metformin therapy is the only oral diabetes drug approved for use in youth with type 2 diabetes. However, metformin works less than 50% of the time in African-American youth and there is marked variability among individuals. Improving outcomes in youth requires understanding the way that drugs such as metformin work in youth and why it does not work in some individuals. New evidence suggests that the ability of metformin to work effectively may be influenced by certain genes or differences in gut bacteria. However, little is known about how genes or gut bacteria may affect youth, especially African-Americans. To treat this aggressive disease, it is also necessary to simultaneously evaluate new therapeutic options, such as combination therapy of metformin with liraglutide in youth at highest risk for complications. Liraglutide is approved to treat type 2 diabetes in patient 10 years and older as an adjunct to diet and exercise. Liraglutide may be a useful early treatment in youth with type 2 diabetes because it may decrease glucose produced by the liver (an early prominent feature of type 2 diabetes in youth). This study is designed to examine the mechanism of action in the liver of these 2 agents and explore how genetic and gut factors may influence this action. The primary objective of this pilot study is to compare the ability of two anti-diabetic regimens (metformin and liraglutide versus metformin alone) to lower gluconeogenesis (glucose produced by the liver) in African-American youth with type 2 diabetes. The secondary objectives are to evaluate the effect of these regimens on the following: (1) hepatic glucose production, and insulin sensitivity and (2) insulin and gut hormones concentrations (e.g. incretins). In addition, we will examine the relationship of known differences in genes associated with metformin transport and action with changes in gluconeogenesis and begin to explore the role of gut bacteria to metformin s glucose-lowering effect. The study design is a parallel-randomized intervention trial of African-American youth with type 2 diabetes who are not on insulin therapy and who are within 5 years of diagnosis. Patients aged 12- 25 years with type 2 diabetes will be enrolled. Participants will be randomized into two intervention arms (16 in each group): metformin and liraglutide versus metformin alone. The study will consist of 5 visits. At Visit 1, a medical history, physical examination and screening labs will be done. Then the eligible participants will undergo a one-week drug-free run-in. At Visit 2 there will be an overnight inpatient stay to perform metabolic testing prior to starting the study drug(s). Participants will start the study drug(s) immediately after Visit 2 and remain on the study drug(s) for 12 weeks. Follow-up monitoring will be performed at 4-week intervals (Visit 3 and 4). The final visit (Visit 5) will occur after 12 weeks. The ultimate goal of this multi-site project is to begin to address diabetes disparities in African-American youth by understanding the mechanism of action of these diabetes agents to inform precision medicine initiatives. This project brings together the skills and expertise of investigators within the National Institute of Diabetes and Digestive Disorders and Kidney Diseases (NIDDK), the National Human Genome Research Institute (NHGRI), and the Children s National Medical Center (CNMC). Patient recruitment and data collection will occur at NIH Clinical Center. Eligible patients may be identified through CNMC but no enrollment, informed consent or study visits will occur at CNMC.

Interventions

DRUGLiraglutide

Liraglutide (6mg/ml, 3ml ) solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6mg, 1.2mg or 1.8mg.

DRUGMetformin

Metformin 500mg oral tablet

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to 25 Years

Healthy volunteers

Inclusion criteria

* INCLUSION CRITERIA: 1. Youth must self-identify as African-American and identify both parents as African-American 2. Age 12-25 years 3. Pubertal or post-pubertal: Girls Tanner stage IV-V breast; Boys Testicular volume 11-25cc 4. Diagnosis of type 2 diabetes of less than or equal to 5 years duration, as per American Diabetes Association Criteria 5. Hemoglobin A1C \<9% at study initiation 6. Negative to mild ketonuria without acidosis (negative or 1+ ketones on urinalysis) 7. Negative test for diabetes-related autoantibodies (glutamic acid decarboxylase 65 and tyrosine phosphatase-related islet antigen 2 (IA-2)) 8. Willing and able to take daily medications and check blood glucose levels at least twice per day or wear a continuous glucose monitoring device (CGM).

Exclusion criteria

1. Pregnancy or breastfeeding 2. Allergy to study medications 3. Allergy to milk protein 4. Chronic insulin therapy 5. Treatment with other medications which are known to affect the parameters under study (for example sodium glucose transporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-IV) inhibitors, non-selective beta blockers). 6. Metabolic derangement such as metabolic acidosis, severe hyperglycemia (fasting blood glucose greater than or equal to 200mg/dL), and/or liver enzymes \> three times the upper limit of normal. 7. Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 8. Any other condition that, in the opinion of the investigators, will increase risk to the subject, or impede the accurate collection of study-related data. 9. Body weight greater than or equal to 450 lbs 10. Body weight less than or equal to 58kg 11. Serum triglyceride concentrations greater than or equal to 500mg/dl 12. Hemoglobin concentration \<10g/dL

Design outcomes

Primary

Measure	Time frame	Description
Change in Absolute Gluconeogenesis From Baseline to 12 Weeks	Baseline to 12 weeks	Gluconeogenesis is measured using stable isotope tracers and is reported as mg/kg lean body mass (LBM) per minute

Secondary

Measure	Time frame	Description
Change in GIP AUC During OGTT and Meal Absorption	Baseline to 12 weeks	Change in glucose-dependent insulinotropic polypeptide (GIP) AUC during OGTT and meal absorption
Change in GLP-1 Area Under the Curve Concentrations (AUC) During OGTT and Meal Absorption	Baseline to 12 weeks	Change in Glucagon-like peptide-1 (GLP-1) area under the curve concentrations (AUC) during OGTT and meal absorption. These data cannot be reported at this time due to problems with the assay. It is expected that a new assay will be available by May 2024
Change in Whole Body Insulin Sensitivity From Baseline to 12 Weeks	Baseline to 12 weeks	Whole body insulin sensitivity is estimated from a model of glucose and insulin values obtained during the OGTT and is measured in 10\^-4 mU/ml/min
Change in Glucose Production Rate From Baseline to 12 Weeks	Baseline to 12 weeks	Glucose production rate is measured using stable isotope tracers and is reported as mg/kg LBM per minute.
Change in Insulin AUC Concentrations During an OGTT and Meal Absorption	Baseline to 12 weeks	Change in insulin AUC as derived from 2-hour oral glucose tolerance test (OGTT). AUC is calculated using a trapezoidal rule. Higher AUC indicates higher insulin secretion
Change in Glycerol Turnover From Baseline to 12 Weeks	Baseline to 12 weeks	Glycerol turnover is measured using stable isotope tracers and is reported as mg/kg LBM per minute.
Change in Palmitate Turnover From Baseline to 12 Weeks	Baseline to 12 weeks	Palmitate turnover is measured using stable isotope tracers and is reported as mg/kg LBM per minute.
Change in Hepatic Insulin Sensitivity Index From Baseline to 12 Weeks	Baseline to 12 weeks	The Hepatic Insulin Sensitivity Index(HISI) is the reciprocal of glucose rate of appearance \[1000/(μmol/min)\] X insulin concentration \[mU/L\]

Countries

United States

Participant flow

Participants by arm

Arm	Count
Metformin Standard release metformin (500 mg tablets) was initiated and titrated to maximum dose of metformin 1000 mg twice daily over 3 weeks and continued for 12 weeks Metformin: Metformin 500mg oral tablet	13
Metformin and Liraglutide Standard release metformin (500 mg tablets) and liraglutide (0.6mg) were initiated and titrated to maximum dose of metformin 1000 mg twice daily, and liraglutide 1.8 mg daily over 3 weeks and continued for 12 weeks Liraglutide: Liraglutide (6mg/ml, 3ml ) solution for subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6mg, 1.2mg or 1.8mg. Metformin: Metformin 500mg oral tablet	11
Total	24

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Poor compliance	0	1
Overall Study	Withdrawal by Subject	1	0

Baseline characteristics

Characteristic	Total	Metformin and Liraglutide	Metformin
Absolute gluconeogenesis	1.81 mg/kg LBM/min STANDARD_DEVIATION 0.34	1.75 mg/kg LBM/min STANDARD_DEVIATION 0.36	1.86 mg/kg LBM/min STANDARD_DEVIATION 0.34
Age, Continuous	15.3 Years STANDARD_DEVIATION 2.1	15.0 Years STANDARD_DEVIATION 2.1	15.6 Years STANDARD_DEVIATION 2.1
Body mass index (BMI)	40.0 kg/m^2 STANDARD_DEVIATION 7.7	38.2 kg/m^2 STANDARD_DEVIATION 8	41.6 kg/m^2 STANDARD_DEVIATION 7.3
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	24 Participants	11 Participants	13 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	0 Participants	0 Participants	0 Participants
Region of Enrollment United States	24 participants	11 participants	13 participants
Sex: Female, Male Female	15 Participants	7 Participants	8 Participants
Sex: Female, Male Male	9 Participants	4 Participants	5 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 13	0 / 11
other Total, other adverse events	6 / 13	7 / 11
serious Total, serious adverse events	0 / 13	0 / 11

Outcome results

Primary

Change in Absolute Gluconeogenesis From Baseline to 12 Weeks

Gluconeogenesis is measured using stable isotope tracers and is reported as mg/kg lean body mass (LBM) per minute